Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 76

1.

The p97-Ataxin 3 complex regulates homeostasis of the DNA damage response E3 ubiquitin ligase RNF8.

Singh AN, Oehler J, Torrecilla I, Kilgas S, Li S, Vaz B, Guérillon C, Fielden J, Hernandez-Carralero E, Cabrera E, Tullis ID, Meerang M, Barber PR, Freire R, Parsons J, Vojnovic B, Kiltie AE, Mailand N, Ramadan K.

EMBO J. 2019 Oct 4;38(21):e102361. doi: 10.15252/embj.2019102361. Epub 2019 Oct 15.

2.

Mouse Models of Muscle-invasive Bladder Cancer: Key Considerations for Clinical Translation Based on Molecular Subtypes.

Ruan JL, Hsu JW, Browning RJ, Stride E, Yildiz YO, Vojnovic B, Kiltie AE.

Eur Urol Oncol. 2019 May;2(3):239-247. doi: 10.1016/j.euo.2018.08.014. Epub 2018 Sep 13. Review.

PMID:
31200837
3.

MRE11 as a Predictive Biomarker of Outcome After Radiation Therapy in Bladder Cancer.

Walker AK, Karaszi K, Valentine H, Strauss VY, Choudhury A, McGill S, Wen K, Brown MD, Ramani V, Bhattarai S, Teo MTW, Yang L, Myers KA, Deshmukh N, Denley H, Browning L, Love SB, Iyer G, Clarke NW, Hall E, Huddart R, James ND, Hoskin PJ, West CML, Kiltie AE.

Int J Radiat Oncol Biol Phys. 2019 Jul 15;104(4):809-818. doi: 10.1016/j.ijrobp.2019.03.015. Epub 2019 Mar 15.

4.

Utility of Bladder-Sparing Therapy vs Radical Cystectomy for Muscle-Invasive Bladder Cancer.

Efstathiou JA, Choudhury A, Kiltie AE.

JAMA Surg. 2019 Feb 1;154(2):184-185. doi: 10.1001/jamasurg.2018.4370. No abstract available.

PMID:
30477011
5.

Harnessing citizen science through mobile phone technology to screen for immunohistochemical biomarkers in bladder cancer.

Smittenaar P, Walker AK, McGill S, Kartsonaki C, Robinson-Vyas RJ, McQuillan JP, Christie S, Harris L, Lawson J, Henderson E, Howat W, Hanby A, Thomas GJ, Bhattarai S, Browning L, Kiltie AE.

Br J Cancer. 2018 Jul;119(2):220-229. doi: 10.1038/s41416-018-0156-0. Epub 2018 Jul 11.

6.

Recommendations for follow-up of muscle-invasive bladder cancer patients: A consensus by the international bladder cancer network.

Zuiverloon TCM, van Kessel KEM, Bivalacqua TJ, Boormans JL, Ecke TH, Grivas PD, Kiltie AE, Liedberg F, Necchi A, van Rhijn BW, Roghmann F, Sanchez-Carbayo M, Schmitz-Dräger BJ, Wezel F, Kamat AM.

Urol Oncol. 2018 Sep;36(9):423-431. doi: 10.1016/j.urolonc.2018.01.014. Epub 2018 Mar 2. Review.

PMID:
29496372
7.

High Levels of Patient Satisfaction in Joint Uro-oncology Clinics to Assist Patient Choice in Early Prostate Cancer and Muscle-invasive Bladder Cancer.

Kiltie AE, Southby R, LeMonnier K, Binnee J, Niederer J, Kartsonaki C, Camilleri P, Sabharwal A, Brewster S, Crew J, Hamdy FC.

Clin Oncol (R Coll Radiol). 2018 Apr;30(4):e39. doi: 10.1016/j.clon.2018.01.004. No abstract available.

PMID:
29395414
8.

No additional prognostic value for MRE11 in squamous cell carcinomas of the anus treated with chemo-radiotherapy.

Walker AK, Kartsonaki C, Collantes E, Nicholson J, Gilbert DC, Kiltie AE.

Br J Cancer. 2018 Jan;118(2):e1. doi: 10.1038/bjc.2017.410. Epub 2018 Jan 11.

9.

Contemporary Patterns of Multidisciplinary Care in Patients With Muscle-invasive Bladder Cancer.

Harshman LC, Tripathi A, Kaag M, Efstathiou JA, Apolo AB, Hoffman-Censits JH, Stadler WM, Yu EY, Bochner BH, Skinner EC, Downs T, Kiltie AE, Bajorin DF, Guru K, Shipley WU, Steinberg GD, Hahn NM, Sridhar SS.

Clin Genitourin Cancer. 2018 Jun;16(3):213-218. doi: 10.1016/j.clgc.2017.11.004. Epub 2017 Dec 6.

10.

Neoadjuvant treatment for muscle-invasive bladder cancer: The past, the present, and the future.

Hermans TJN, Voskuilen CS, van der Heijden MS, Schmitz-Dräger BJ, Kassouf W, Seiler R, Kamat AM, Grivas P, Kiltie AE, Black PC, van Rhijn BWG.

Urol Oncol. 2018 Sep;36(9):413-422. doi: 10.1016/j.urolonc.2017.10.014. Epub 2017 Nov 8. Review.

PMID:
29128420
11.

Radiosensitization In Vivo by Histone Deacetylase Inhibition with No Increase in Early Normal Tissue Radiation Toxicity.

Groselj B, Ruan JL, Scott H, Gorrill J, Nicholson J, Kelly J, Anbalagan S, Thompson J, Stratford MRL, Jevons SJ, Hammond EM, Scudamore CL, Kerr M, Kiltie AE.

Mol Cancer Ther. 2018 Feb;17(2):381-392. doi: 10.1158/1535-7163.MCT-17-0011. Epub 2017 Aug 24.

12.

No additional prognostic value for MRE11 in squamous cell carcinomas of the anus treated with chemo-radiotherapy.

Walker AK, Kartsonaki C, Collantes E, Nicholson J, Gilbert DC, Kiltie AE.

Br J Cancer. 2017 Jul 25;117(3):322-325. doi: 10.1038/bjc.2017.188. Epub 2017 Jun 22. Erratum in: Br J Cancer. 2018 Jan 11;:.

13.

Genetic Alterations in the Molecular Subtypes of Bladder Cancer: Illustration in the Cancer Genome Atlas Dataset.

Choi W, Ochoa A, McConkey DJ, Aine M, Höglund M, Kim WY, Real FX, Kiltie AE, Milsom I, Dyrskjøt L, Lerner SP.

Eur Urol. 2017 Sep;72(3):354-365. doi: 10.1016/j.eururo.2017.03.010. Epub 2017 Mar 30. Review.

14.

E3 Ligase cIAP2 Mediates Downregulation of MRE11 and Radiosensitization in Response to HDAC Inhibition in Bladder Cancer.

Nicholson J, Jevons SJ, Groselj B, Ellermann S, Konietzny R, Kerr M, Kessler BM, Kiltie AE.

Cancer Res. 2017 Jun 1;77(11):3027-3039. doi: 10.1158/0008-5472.CAN-16-3232. Epub 2017 Mar 31.

15.

The Impact of Histological Variants of Urothelial Carcinoma on Clinical Outcomes Following Trimodality Bladder-sparing Chemoradiation.

Kiltie AE, Browning L.

Eur Urol. 2017 Jul;72(1):61-63. doi: 10.1016/j.eururo.2017.01.045. Epub 2017 Feb 14. No abstract available.

PMID:
28214031
16.

The National Institute for Health and Care Excellence (NICE) Guidance on Bladder Cancer; a Step in the Right Direction?

Trainor S, Choudhury A, Huddart R, Kiltie AE, Kockelbergh R, Turner W, Birtle A, Crabb SJ.

Clin Oncol (R Coll Radiol). 2017 Jun;29(6):344-347. doi: 10.1016/j.clon.2017.01.040. Epub 2017 Feb 9. No abstract available.

PMID:
28190637
17.

Crowdsourcing for translational research: analysis of biomarker expression using cancer microarrays.

Lawson J, Robinson-Vyas RJ, McQuillan JP, Paterson A, Christie S, Kidza-Griffiths M, McDuffus LA, Moutasim KA, Shaw EC, Kiltie AE, Howat WJ, Hanby AM, Thomas GJ, Smittenaar P.

Br J Cancer. 2017 Jan 17;116(2):237-245. doi: 10.1038/bjc.2016.404. Epub 2016 Dec 13.

18.

Corrigendum to "Treatment of Breast and Prostate Cancer by Hypofractionated Radiotherapy: Potential Risks and Benefits" [Clin Oncol 27 (7) (2015) 420-426].

Ray KJ, Sibson NR, Kiltie AE.

Clin Oncol (R Coll Radiol). 2016 Feb;28(2):161. doi: 10.1016/j.clon.2015.11.009. Epub 2015 Dec 9. No abstract available.

19.

Identification of a novel susceptibility locus at 13q34 and refinement of the 20p12.2 region as a multi-signal locus associated with bladder cancer risk in individuals of European ancestry.

Figueroa JD, Middlebrooks CD, Banday AR, Ye Y, Garcia-Closas M, Chatterjee N, Koutros S, Kiemeney LA, Rafnar T, Bishop T, Furberg H, Matullo G, Golka K, Gago-Dominguez M, Taylor JA, Fletcher T, Siddiq A, Cortessis VK, Kooperberg C, Cussenot O, Benhamou S, Prescott J, Porru S, Dinney CP, Malats N, Baris D, Purdue MP, Jacobs EJ, Albanes D, Wang Z, Chung CC, Vermeulen SH, Aben KK, Galesloot TE, Thorleifsson G, Sulem P, Stefansson K, Kiltie AE, Harland M, Teo M, Offit K, Vijai J, Bajorin D, Kopp R, Fiorito G, Guarrera S, Sacerdote C, Selinski S, Hengstler JG, Gerullis H, Ovsiannikov D, Blaszkewicz M, Castelao JE, Calaza M, Martinez ME, Cordeiro P, Xu Z, Panduri V, Kumar R, Gurzau E, Koppova K, Bueno-De-Mesquita HB, Ljungberg B, Clavel-Chapelon F, Weiderpass E, Krogh V, Dorronsoro M, Travis RC, Tjønneland A, Brennan P, Chang-Claude J, Riboli E, Conti D, Stern MC, Pike MC, Van Den Berg D, Yuan JM, Hohensee C, Jeppson RP, Cancel-Tassin G, Roupret M, Comperat E, Turman C, De Vivo I, Giovannucci E, Hunter DJ, Kraft P, Lindstrom S, Carta A, Pavanello S, Arici C, Mastrangelo G, Kamat AM, Zhang L, Gong Y, Pu X, Hutchinson A, Burdett L, Wheeler WA, Karagas MR, Johnson A, Schned A, Monawar Hosain GM, Schwenn M, Kogevinas M, Tardón A, Serra C, Carrato A, García-Closas R, Lloreta J, Andriole G Jr, Grubb R 3rd, Black A, Diver WR, Gapstur SM, Weinstein S, Virtamo J, Haiman CA, Landi MT, Caporaso NE, Fraumeni JF Jr, Vineis P, Wu X, Chanock SJ, Silverman DT, Prokunina-Olsson L, Rothman N.

Hum Mol Genet. 2016 Mar 15;25(6):1203-14. doi: 10.1093/hmg/ddv492. Epub 2016 Jan 4.

20.

Biomarkers of Tumour Radiosensitivity and Predicting Benefit from Radiotherapy.

Forker LJ, Choudhury A, Kiltie AE.

Clin Oncol (R Coll Radiol). 2015 Oct;27(10):561-9. doi: 10.1016/j.clon.2015.06.002. Epub 2015 Jun 26. Review.

PMID:
26119726
21.

High-throughput DNA Sequencing Identifies Novel CtIP (RBBP8) Variants in Muscle-invasive Bladder Cancer Patients.

Jevons SJ, Green A, Lunter G, Kartsonaki C, Buck D, Piazza P, Kiltie AE.

Bladder Cancer. 2015 Apr 30;1(1):31-44. doi: 10.3233/BLC-150007.

22.

Treatment of Breast and Prostate Cancer by Hypofractionated Radiotherapy: Potential Risks and Benefits.

Ray KJ, Sibson NR, Kiltie AE.

Clin Oncol (R Coll Radiol). 2015 Jul;27(7):420-6. doi: 10.1016/j.clon.2015.02.008. Epub 2015 Mar 7. Review. Erratum in: Clin Oncol (R Coll Radiol). 2016 Feb;28(2):161.

23.

Words of wisdom. Re: Critical analysis of bladder sparing with trimodal therapy in muscle-invasive bladder cancer: a systematic review.

Kiltie AE.

Eur Urol. 2014 Sep;66(3):597-8. doi: 10.1016/j.eururo.2014.06.033. No abstract available.

PMID:
25306182
24.

Deoxycytidine kinase expression underpins response to gemcitabine in bladder cancer.

Kerr M, Scott HE, Groselj B, Stratford MR, Karaszi K, Sharma NL, Kiltie AE.

Clin Cancer Res. 2014 Nov 1;20(21):5435-45. doi: 10.1158/1078-0432.CCR-14-0542. Epub 2014 Sep 15.

25.

Genome-wide association study yields variants at 20p12.2 that associate with urinary bladder cancer.

Rafnar T, Sulem P, Thorleifsson G, Vermeulen SH, Helgason H, Saemundsdottir J, Gudjonsson SA, Sigurdsson A, Stacey SN, Gudmundsson J, Johannsdottir H, Alexiusdottir K, Petursdottir V, Nikulasson S, Geirsson G, Jonsson T, Aben KK, Grotenhuis AJ, Verhaegh GW, Dudek AM, Witjes JA, van der Heijden AG, Vrieling A, Galesloot TE, De Juan A, Panadero A, Rivera F, Hurst C, Bishop DT, Sak SC, Choudhury A, Teo MT, Arici C, Carta A, Toninelli E, de Verdier P, Rudnai P, Gurzau E, Koppova K, van der Keur KA, Lurkin I, Goossens M, Kellen E, Guarrera S, Russo A, Critelli R, Sacerdote C, Vineis P, Krucker C, Zeegers MP, Gerullis H, Ovsiannikov D, Volkert F, Hengstler JG, Selinski S, Magnusson OT, Masson G, Kong A, Gudbjartsson D, Lindblom A, Zwarthoff E, Porru S, Golka K, Buntinx F, Matullo G, Kumar R, Mayordomo JI, Steineck DG, Kiltie AE, Jonsson E, Radvanyi F, Knowles MA, Thorsteinsdottir U, Kiemeney LA, Stefansson K.

Hum Mol Genet. 2014 Oct 15;23(20):5545-57. doi: 10.1093/hmg/ddu264. Epub 2014 May 26.

26.

Whole-genome sequencing of bladder cancers reveals somatic CDKN1A mutations and clinicopathological associations with mutation burden.

Cazier JB, Rao SR, McLean CM, Walker AK, Wright BJ, Jaeger EE, Kartsonaki C, Marsden L, Yau C, Camps C, Kaisaki P; Oxford-Illumina WGS500 Consortium, Taylor J, Catto JW, Tomlinson IP, Kiltie AE, Hamdy FC.

Nat Commun. 2014 Apr 29;5:3756. doi: 10.1038/ncomms4756. Erratum in: Nat Commun. 2014;5:4809. Walker, A L [corrected to Walker, A K].

27.

Post-transcriptional regulation of MRE11 expression in muscle-invasive bladder tumours.

Martin RM, Kerr M, Teo MT, Jevons SJ, Koritzinsky M, Wouters BG, Bhattarai S, Kiltie AE.

Oncotarget. 2014 Feb 28;5(4):993-1003.

28.

Next-generation sequencing identifies germline MRE11A variants as markers of radiotherapy outcomes in muscle-invasive bladder cancer.

Teo MT, Dyrskjøt L, Nsengimana J, Buchwald C, Snowden H, Morgan J, Jensen JB, Knowles MA, Taylor G, Barrett JH, Borre M, Orntoft TF, Bishop DT, Kiltie AE.

Ann Oncol. 2014 Apr;25(4):877-83. doi: 10.1093/annonc/mdu014. Epub 2014 Mar 12.

29.

Can γH2AX be used to personalise cancer treatment?

Shah K, Cornelissen B, Kiltie AE, Vallis KA.

Curr Mol Med. 2013 Dec;13(10):1591-602. Review.

PMID:
24206133
30.

Radiosensitisation of bladder cancer cells by panobinostat is modulated by Ku80 expression.

Groselj B, Kerr M, Kiltie AE.

Radiother Oncol. 2013 Sep;108(3):429-33. doi: 10.1016/j.radonc.2013.06.021. Epub 2013 Aug 6.

31.

The emerging role of histone deacetylase (HDAC) inhibitors in urological cancers.

Sharma NL, Groselj B, Hamdy FC, Kiltie AE.

BJU Int. 2013 Apr;111(4):537-42. doi: 10.1111/j.1464-410X.2012.11647.x. Review.

32.

Histone deacetylase inhibitors as radiosensitisers: effects on DNA damage signalling and repair.

Groselj B, Sharma NL, Hamdy FC, Kerr M, Kiltie AE.

Br J Cancer. 2013 Mar 5;108(4):748-54. doi: 10.1038/bjc.2013.21. Epub 2013 Jan 29. Review.

33.

Imatinib radiosensitizes bladder cancer by targeting homologous recombination.

Qiao B, Kerr M, Groselj B, Teo MT, Knowles MA, Bristow RG, Phillips RM, Kiltie AE.

Cancer Res. 2013 Mar 1;73(5):1611-20. doi: 10.1158/0008-5472.CAN-12-1170. Epub 2013 Jan 9.

34.

Using gene polymorphisms to assess bladder cancer risk: progress and challenges.

Kiltie AE.

J Urol. 2012 Feb;187(2):379-80. doi: 10.1016/j.juro.2011.11.002. Epub 2011 Dec 15. No abstract available.

PMID:
22177142
35.

The role of microRNA-binding site polymorphisms in DNA repair genes as risk factors for bladder cancer and breast cancer and their impact on radiotherapy outcomes.

Teo MT, Landi D, Taylor CF, Elliott F, Vaslin L, Cox DG, Hall J, Landi S, Bishop DT, Kiltie AE.

Carcinogenesis. 2012 Mar;33(3):581-6. doi: 10.1093/carcin/bgr300. Epub 2011 Dec 12.

36.

European genome-wide association study identifies SLC14A1 as a new urinary bladder cancer susceptibility gene.

Rafnar T, Vermeulen SH, Sulem P, Thorleifsson G, Aben KK, Witjes JA, Grotenhuis AJ, Verhaegh GW, Hulsbergen-van de Kaa CA, Besenbacher S, Gudbjartsson D, Stacey SN, Gudmundsson J, Johannsdottir H, Bjarnason H, Zanon C, Helgadottir H, Jonasson JG, Tryggvadottir L, Jonsson E, Geirsson G, Nikulasson S, Petursdottir V, Bishop DT, Chung-Sak S, Choudhury A, Elliott F, Barrett JH, Knowles MA, de Verdier PJ, Ryk C, Lindblom A, Rudnai P, Gurzau E, Koppova K, Vineis P, Polidoro S, Guarrera S, Sacerdote C, Panadero A, Sanz-Velez JI, Sanchez M, Valdivia G, Garcia-Prats MD, Hengstler JG, Selinski S, Gerullis H, Ovsiannikov D, Khezri A, Aminsharifi A, Malekzadeh M, van den Berg LH, Ophoff RA, Veldink JH, Zeegers MP, Kellen E, Fostinelli J, Andreoli D, Arici C, Porru S, Buntinx F, Ghaderi A, Golka K, Mayordomo JI, Matullo G, Kumar R, Steineck G, Kiltie AE, Kong A, Thorsteinsdottir U, Stefansson K, Kiemeney LA.

Hum Mol Genet. 2011 Nov 1;20(21):4268-81. doi: 10.1093/hmg/ddr303. Epub 2011 Jul 12.

37.

Radiotherapy for node positive penile cancer: experience of the Leeds teaching hospitals.

Franks KN, Kancherla K, Sethugavalar B, Whelan P, Eardley I, Kiltie AE.

J Urol. 2011 Aug;186(2):524-9. doi: 10.1016/j.juro.2011.03.117. Epub 2011 Jun 22.

PMID:
21700296
38.

Functional assays to determine the significance of two common XPC 3'UTR variants found in bladder cancer patients.

Qiao B, Scott GB, Elliott F, Vaslin L, Bentley J, Hall J, Bishop DT, Knowles MA, Kiltie AE.

BMC Med Genet. 2011 Jun 20;12:84. doi: 10.1186/1471-2350-12-84.

39.

In vitro functional effects of XPC gene rare variants from bladder cancer patients.

Qiao B, Ansari AH, Scott GB, Sak SC, Chambers PA, Elliott F, Teo MT, Bentley J, Churchman M, Hall J, Taylor CF, Bishop TD, Knowles MA, Kiltie AE.

Carcinogenesis. 2011 Apr;32(4):516-21. doi: 10.1093/carcin/bgr005. Epub 2011 Jan 27.

40.

Phase II study of conformal hypofractionated radiotherapy with concurrent gemcitabine in muscle-invasive bladder cancer.

Choudhury A, Swindell R, Logue JP, Elliott PA, Livsey JE, Wise M, Symonds P, Wylie JP, Ramani V, Sangar V, Lyons J, Bottomley I, McCaul D, Clarke NW, Kiltie AE, Cowan RA.

J Clin Oncol. 2011 Feb 20;29(6):733-8. doi: 10.1200/JCO.2010.31.5721. Epub 2011 Jan 4.

PMID:
21205754
41.

A multi-stage genome-wide association study of bladder cancer identifies multiple susceptibility loci.

Rothman N, Garcia-Closas M, Chatterjee N, Malats N, Wu X, Figueroa JD, Real FX, Van Den Berg D, Matullo G, Baris D, Thun M, Kiemeney LA, Vineis P, De Vivo I, Albanes D, Purdue MP, Rafnar T, Hildebrandt MA, Kiltie AE, Cussenot O, Golka K, Kumar R, Taylor JA, Mayordomo JI, Jacobs KB, Kogevinas M, Hutchinson A, Wang Z, Fu YP, Prokunina-Olsson L, Burdett L, Yeager M, Wheeler W, Tardón A, Serra C, Carrato A, García-Closas R, Lloreta J, Johnson A, Schwenn M, Karagas MR, Schned A, Andriole G Jr, Grubb R 3rd, Black A, Jacobs EJ, Diver WR, Gapstur SM, Weinstein SJ, Virtamo J, Cortessis VK, Gago-Dominguez M, Pike MC, Stern MC, Yuan JM, Hunter DJ, McGrath M, Dinney CP, Czerniak B, Chen M, Yang H, Vermeulen SH, Aben KK, Witjes JA, Makkinje RR, Sulem P, Besenbacher S, Stefansson K, Riboli E, Brennan P, Panico S, Navarro C, Allen NE, Bueno-de-Mesquita HB, Trichopoulos D, Caporaso N, Landi MT, Canzian F, Ljungberg B, Tjonneland A, Clavel-Chapelon F, Bishop DT, Teo MT, Knowles MA, Guarrera S, Polidoro S, Ricceri F, Sacerdote C, Allione A, Cancel-Tassin G, Selinski S, Hengstler JG, Dietrich H, Fletcher T, Rudnai P, Gurzau E, Koppova K, Bolick SC, Godfrey A, Xu Z, Sanz-Velez JI, D García-Prats M, Sanchez M, Valdivia G, Porru S, Benhamou S, Hoover RN, Fraumeni JF Jr, Silverman DT, Chanock SJ.

Nat Genet. 2010 Nov;42(11):978-84. doi: 10.1038/ng.687. Epub 2010 Oct 24.

42.

MRE11 expression is predictive of cause-specific survival following radical radiotherapy for muscle-invasive bladder cancer.

Choudhury A, Nelson LD, Teo MT, Chilka S, Bhattarai S, Johnston CF, Elliott F, Lowery J, Taylor CF, Churchman M, Bentley J, Knowles MA, Harnden P, Bristow RG, Bishop DT, Kiltie AE.

Cancer Res. 2010 Sep 15;70(18):7017-26. doi: 10.1158/0008-5472.CAN-10-1202.

43.

A sequence variant at 4p16.3 confers susceptibility to urinary bladder cancer.

Kiemeney LA, Sulem P, Besenbacher S, Vermeulen SH, Sigurdsson A, Thorleifsson G, Gudbjartsson DF, Stacey SN, Gudmundsson J, Zanon C, Kostic J, Masson G, Bjarnason H, Palsson ST, Skarphedinsson OB, Gudjonsson SA, Witjes JA, Grotenhuis AJ, Verhaegh GW, Bishop DT, Sak SC, Choudhury A, Elliott F, Barrett JH, Hurst CD, de Verdier PJ, Ryk C, Rudnai P, Gurzau E, Koppova K, Vineis P, Polidoro S, Guarrera S, Sacerdote C, Campagna M, Placidi D, Arici C, Zeegers MP, Kellen E, Gutierrez BS, Sanz-Velez JI, Sanchez-Zalabardo M, Valdivia G, Garcia-Prats MD, Hengstler JG, Blaszkewicz M, Dietrich H, Ophoff RA, van den Berg LH, Alexiusdottir K, Kristjansson K, Geirsson G, Nikulasson S, Petursdottir V, Kong A, Thorgeirsson T, Mungan NA, Lindblom A, van Es MA, Porru S, Buntinx F, Golka K, Mayordomo JI, Kumar R, Matullo G, Steineck G, Kiltie AE, Aben KK, Jonsson E, Thorsteinsdottir U, Knowles MA, Rafnar T, Stefansson K.

Nat Genet. 2010 May;42(5):415-9. doi: 10.1038/ng.558. Epub 2010 Mar 28.

44.

Common predisposition alleles for moderately common cancers: bladder cancer.

Kiltie AE.

Curr Opin Genet Dev. 2010 Jun;20(3):218-24. doi: 10.1016/j.gde.2010.01.002. Epub 2010 Feb 12. Review.

PMID:
20153630
45.

Polymorphisms in DNA repair genes, smoking, and bladder cancer risk: findings from the international consortium of bladder cancer.

Stern MC, Lin J, Figueroa JD, Kelsey KT, Kiltie AE, Yuan JM, Matullo G, Fletcher T, Benhamou S, Taylor JA, Placidi D, Zhang ZF, Steineck G, Rothman N, Kogevinas M, Silverman D, Malats N, Chanock S, Wu X, Karagas MR, Andrew AS, Nelson HH, Bishop DT, Sak SC, Choudhury A, Barrett JH, Elliot F, Corral R, Joshi AD, Gago-Dominguez M, Cortessis VK, Xiang YB, Gao YT, Vineis P, Sacerdote C, Guarrera S, Polidoro S, Allione A, Gurzau E, Koppova K, Kumar R, Rudnai P, Porru S, Carta A, Campagna M, Arici C, Park SS, Garcia-Closas M; International Consortium of Bladder Cancer.

Cancer Res. 2009 Sep 1;69(17):6857-64. doi: 10.1158/0008-5472.CAN-09-1091. Epub 2009 Aug 25.

46.

Genetic variation in the prostate stem cell antigen gene PSCA confers susceptibility to urinary bladder cancer.

Wu X, Ye Y, Kiemeney LA, Sulem P, Rafnar T, Matullo G, Seminara D, Yoshida T, Saeki N, Andrew AS, Dinney CP, Czerniak B, Zhang ZF, Kiltie AE, Bishop DT, Vineis P, Porru S, Buntinx F, Kellen E, Zeegers MP, Kumar R, Rudnai P, Gurzau E, Koppova K, Mayordomo JI, Sanchez M, Saez B, Lindblom A, de Verdier P, Steineck G, Mills GB, Schned A, Guarrera S, Polidoro S, Chang SC, Lin J, Chang DW, Hale KS, Majewski T, Grossman HB, Thorlacius S, Thorsteinsdottir U, Aben KK, Witjes JA, Stefansson K, Amos CI, Karagas MR, Gu J.

Nat Genet. 2009 Sep;41(9):991-5. doi: 10.1038/ng.421. Epub 2009 Aug 2. Erratum in: Nat Genet. 2009 Oct;41(10):1156. Guarrera, Simonetta [added]; Polidoro, Silvia [added].

47.

Sequence variants at the TERT-CLPTM1L locus associate with many cancer types.

Rafnar T, Sulem P, Stacey SN, Geller F, Gudmundsson J, Sigurdsson A, Jakobsdottir M, Helgadottir H, Thorlacius S, Aben KK, Blöndal T, Thorgeirsson TE, Thorleifsson G, Kristjansson K, Thorisdottir K, Ragnarsson R, Sigurgeirsson B, Skuladottir H, Gudbjartsson T, Isaksson HJ, Einarsson GV, Benediktsdottir KR, Agnarsson BA, Olafsson K, Salvarsdottir A, Bjarnason H, Asgeirsdottir M, Kristinsson KT, Matthiasdottir S, Sveinsdottir SG, Polidoro S, Höiom V, Botella-Estrada R, Hemminki K, Rudnai P, Bishop DT, Campagna M, Kellen E, Zeegers MP, de Verdier P, Ferrer A, Isla D, Vidal MJ, Andres R, Saez B, Juberias P, Banzo J, Navarrete S, Tres A, Kan D, Lindblom A, Gurzau E, Koppova K, de Vegt F, Schalken JA, van der Heijden HF, Smit HJ, Termeer RA, Oosterwijk E, van Hooij O, Nagore E, Porru S, Steineck G, Hansson J, Buntinx F, Catalona WJ, Matullo G, Vineis P, Kiltie AE, Mayordomo JI, Kumar R, Kiemeney LA, Frigge ML, Jonsson T, Saemundsson H, Barkardottir RB, Jonsson E, Jonsson S, Olafsson JH, Gulcher JR, Masson G, Gudbjartsson DF, Kong A, Thorsteinsdottir U, Stefansson K.

Nat Genet. 2009 Feb;41(2):221-7. doi: 10.1038/ng.296. Epub 2009 Jan 18.

48.

Targeting homologous recombination using imatinib results in enhanced tumor cell chemosensitivity and radiosensitivity.

Choudhury A, Zhao H, Jalali F, Al Rashid S, Ran J, Supiot S, Kiltie AE, Bristow RG.

Mol Cancer Ther. 2009 Jan;8(1):203-13. doi: 10.1158/1535-7163.MCT-08-0959.

49.

Molecular epidemiology of DNA repair genes in bladder cancer.

Kiltie AE.

Methods Mol Biol. 2009;472:281-306. doi: 10.1007/978-1-60327-492-0_12. Review.

PMID:
19107438
50.

Papillary and muscle invasive bladder tumors with distinct genomic stability profiles have different DNA repair fidelity and KU DNA-binding activities.

Bentley J, L'Hôte C, Platt F, Hurst CD, Lowery J, Taylor C, Sak SC, Harnden P, Knowles MA, Kiltie AE.

Genes Chromosomes Cancer. 2009 Apr;48(4):310-21. doi: 10.1002/gcc.20641.

PMID:
19105236

Supplemental Content

Loading ...
Support Center